Laura Brege's most recent trade in Edgewise Therapeutics Inc was a trade of 30,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,279 | 11,279 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 6,163 | 23,715 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Sale of securities on an exchange or to another person at price $ 21.78 per share. | 04 Jun 2025 | 14,446 | 15,095 (0%) | 0% | 21.8 | 314,634 | Common Stock |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 13,793 | 13,793 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 29,541 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 8,107 | 8,107 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 6,268 | 6,268 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 5,703 | 15,703 (0%) | 0% | - | Common Stock | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 5,703 | 0 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 3,977 | 3,977 | - | - | Deferred Stock Units | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Purchase of securities on an exchange or from another person at price $ 12.81 per share. | 16 Aug 2024 | 1,000 | 17,552 (0%) | 0% | 12.8 | 12,810 | Common Stock |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,179 | 12,179 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 5,230 | 16,552 (0%) | 0% | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 20,594 | 20,594 | - | - | Stock Option (Right to Buy) | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 8,779 | 8,779 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,703 | 5,703 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 15,959 | 15,959 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 9,387 | 9,387 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 20,154 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 6,652 | 0 | - | - | Restricted Stock Units | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,925 | 12,925 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 1,775 | 11,322 (0%) | 0% | 0 | Common Stock | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Sale of securities on an exchange or to another person at price $ 38.74 per share. | 05 Jun 2023 | 600 | 9,547 (0%) | 0% | 38.7 | 23,244 | Common Stock |
| Pacira BioSciences Inc | Laura A. Brege | Director | Sale of securities on an exchange or to another person at price $ 40.72 per share. | 03 Apr 2023 | 7,000 | 10,147 (0%) | 0% | 40.7 | 285,040 | Common Stock |
| Pacira BioSciences Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2023 | 7,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.90 per share. | 03 Apr 2023 | 7,000 | 17,147 (0%) | 0% | 29.9 | 209,300 | Common Stock |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.01 per share. | 12 Jan 2023 | 12,500 | 12,500 (0%) | 0% | 17.0 | 212,625 | Common Stock |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2023 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Sale of securities on an exchange or to another person at price $ 18.25 per share. | 12 Jan 2023 | 12,500 | 0 (0%) | 0% | 18.3 | 228,125 | Common Stock |
| Edgewise Therapeutics Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 42,087 | 42,087 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 8,225 | 8,225 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 1,160 | 10,147 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 14,368 | 14,368 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 8,552 | 8,552 | - | - | Restricted Stock Units | |
| Mirum Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,637 | 11,637 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,045 | 11,045 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 8,552 | 18,002 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,652 | 6,652 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 6,391 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 6,391 | 9,450 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Laura A. Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2021 | 3,059 | 3,059 (0%) | 0% | - | Common Stock | |
| Mirum Pharmaceuticals Inc | Laura Brege | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Pacira BioSciences Inc | Laura Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.98 per share. | 16 Nov 2020 | 12,000 | 19,921 (0%) | 0% | 14.0 | 167,760 | Common Stock |
| Pacira BioSciences Inc | Laura Brege | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Laura Brege | Director | Sale of securities on an exchange or to another person at price $ 65.95 per share. | 16 Nov 2020 | 12,000 | 7,921 (0%) | 0% | 66.0 | 791,400 | Common Stock |